Inventiva (NASDAQ:IVA) Shares Gap Down – Should You Sell?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) gapped down prior to trading on Friday . The stock had previously closed at $5.77, but opened at $5.44. Inventiva shares last traded at $5.54, with a volume of 5,620 shares trading hands.

Analysts Set New Price Targets

A number of analysts have recently weighed in on IVA shares. Guggenheim boosted their target price on shares of Inventiva from $9.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. HC Wainwright started coverage on Inventiva in a research report on Wednesday, September 3rd. They issued a “buy” rating and a $20.00 price target for the company. Finally, Piper Sandler started coverage on Inventiva in a research report on Wednesday, August 27th. They issued an “overweight” rating and a $26.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $14.83.

Inventiva Trading Down 2.8%

The firm’s fifty day moving average is $4.15 and its 200 day moving average is $3.56.

Hedge Funds Weigh In On Inventiva

An institutional investor recently bought a new position in Inventiva stock. Wealth Enhancement Advisory Services LLC bought a new position in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 10,715 shares of the company’s stock, valued at approximately $32,000. 19.06% of the stock is owned by institutional investors.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.